Presenter: Dr. Bridgette McNally 

Title: Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis

Learning Objectives
Upon completion of this activity, participants should be able to:

• Recognize the definitions of MASLD and MASH
• Describe and emphasize the importance of treatment/management of MASLD
• Discuss the mechanism of action of Tirzepatide
• Compare the effects of Tirzepatide vs placebo in the management of MASH
   

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.